BIOCAPTIVA Raises £1.58M and Enters US Liquid Biopsy Market
Scottish diagnostics innovator BIOCAPTIVA has secured a fresh funding round of £1.58 million and launched its first liquid biopsy kits in the United States, marking a pivotal step in its ambition to reshape how cancers and other serious diseases are detected and monitored.
Targeting Earlier, Less Invasive Cancer Detection
BIOCAPTIVA focuses on capturing and analysing cell-free DNA (cfDNA) from blood samples, a core component of modern liquid biopsy technologies. By extracting genetic material shed by tumours into the bloodstream, liquid biopsies offer a less invasive alternative to traditional tissue biopsies and open the door to earlier detection, treatment monitoring and recurrence tracking.
The newly launched kits are designed for use by US clinical research laboratories and biopharma partners. They aim to improve the sensitivity and consistency of cfDNA collection, a critical bottleneck for many emerging precision oncology tests and companion diagnostics.
Funding to Accelerate Commercial and Clinical Expansion
The £1.58M raise will support scale-up of manufacturing, regulatory activities and expanded validation studies with leading US and European centres. The company plans to deepen collaborations with oncology researchers, pharmaceutical developers and reference laboratories that are building next-generation genomic assays.
Industry analysts note that the global liquid biopsy market is growing rapidly, driven by demand for minimally invasive testing and the rise of targeted therapies. By providing high-quality sample collection tools, BIOCAPTIVA is positioning itself as an enabling player within this ecosystem rather than a direct competitor to test developers.
Strategic Positioning in a Competitive Medtech Landscape
The US launch represents a significant validation step for the company’s technology and quality systems, given the market’s stringent expectations around clinical evidence and regulatory compliance. The new capital will also be used to strengthen the commercial team, expand distribution partnerships and support ongoing R&D into next-generation collection devices.
With demand rising for reliable biospecimen collection in large-scale clinical trials and real-world evidence studies, BIOCAPTIVA is aiming to become a preferred partner for organisations seeking robust, scalable solutions for liquid biopsy-based programmes.